Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

This study has been completed.
Grifols Therapeutics Inc.
Information provided by:
The Center for Rheumatic Disease, Allergy, & Immunology Identifier:
First received: December 28, 2006
Last updated: December 29, 2006
Last verified: December 2006
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: December 2006
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):